Cramer's lightning round: This DuPont spin-off has moved too much

Source: CNBC. Jim Cramer flew through his take on callers' favorite stocks, including a pharmaceutical play undergoing a turnaround.·CNBC

It's that time again! Jim Cramer rang the lightning round bell, which means he gave his take on caller favorite stocks at rapid speed:

Chemours (NYSE: CC): "Man, that's a spin-off of DuPont (NYSE: DD) that I think has had too much of a move, and I can't tell you to buy it at this level."

Charles Schwab (NYSE: SCHW): "I like the stock of Schwab. I think that rates are going higher and that's very good for them."

Essent Group (NYSE: ESNT): "It's mortgage insurance, which I think has been historically a good business. I like it."

Cara Therapeutics (NASDAQ: CARA): "I believe in Cara. We had them on. Unfortunately, the stock has done absolutely nothing, but I do believe in them and I think the drug is a good one – the anti-itch part especially. So I'm sticking with it."

MGM Growth Properties (NYSE: MGP): "I like that, too. I happen to be a big fan of what [Chairman of the Board] Jim Murren has put together. I like it very much."

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer's world? Hit him up!
Mad Money Twitter - Jim Cramer Twitter - Facebook - Instagram - Vine

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com



More From CNBC

Advertisement